Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022

Tebentafusp Granted Rare EU Accelerated Assessment

 
• By Andrew McConaghie
  
EMA
Rapid assessment US and EU reviews could see tebentafusp become the TCR receptor therapy approved in early 2022
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip